Stock analysts at Wedbush assumed coverage on shares of Ascendis Pharma AS (NASDAQ:ASND) in a research note issued to investors on Monday. The brokerage set an “outperform” rating and a $34.00 price target on the stock. Wedbush’s price target would indicate a potential upside of 61.83% from the company’s current price.
Other research analysts have also issued research reports about the stock. Leerink Swann reissued a “buy” rating on shares of Ascendis Pharma AS in a research note on Friday, September 2nd. Zacks Investment Research raised shares of Ascendis Pharma AS from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a research note on Monday, August 15th. Finally, TheStreet raised shares of Ascendis Pharma AS from a “sell” rating to a “hold” rating in a research note on Tuesday, September 6th.
Ascendis Pharma AS (NASDAQ:ASND) opened at 21.01 on Monday. Ascendis Pharma AS has a 52 week low of $11.92 and a 52 week high of $21.70. The firm’s 50-day moving average is $18.53 and its 200-day moving average is $16.06. The firm’s market cap is $529.30 million.
Ascendis Pharma AS (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, August 31st. The company reported ($0.59) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.10. On average, equities analysts anticipate that Ascendis Pharma AS will post ($3.14) earnings per share for the current year.
Ascendis Pharma AS Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma AS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma AS and related companies with MarketBeat.com's FREE daily email newsletter.